
Alkermes (ALKS) Stock Forecast & Price Target
Alkermes (ALKS) Analyst Ratings
Bulls say
Alkermes is currently trading at a low P/S ratio in comparison to its industry peers and has shown strong revenue growth in recent years. Alkermes' stock has potential for growth, with a focus on developing treatments for psychiatric diseases and promising pipeline assets. Upcoming data for drugs targeting sleep disorders and ADHD could further drive the stock's success. The company's low P/S ratio and strong revenue growth make it an attractive investment opportunity with potential for competition and M&A activity.
Bears say
Alkermes is facing challenges in differentiating their drug efficacy, with low diagnosis rates and few approved treatments, placing them at a disadvantage to competitors. Despite their recent acquisition and position in the market, their long-term growth outlook and potential for disruptions in the standard-of-care appears low, leading to a negative outlook on their stock. Their financials, such as their discounted cash flow analysis and small ph1b study, do not inspire confidence in the potential success of their products.
This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.
Alkermes (ALKS) Analyst Forecast & Price Prediction
Start investing in Alkermes (ALKS)
Order type
Buy in
Order amount
Est. shares
0 shares